Allie Karas, MA

Discover the latest advancements in pediatric atopic dermatitis care, featuring expert insights on innovative treatments and family-centered management strategies.

In this Maui Derm NP+PA Fall session, Tsao discusses the growing trend of TIL therapy and neoadjuvant treatment for pigmented lesions, as well as atypical clinical presentation.

In her session at Maui Derm NP+PA Fall, Culton also emphasized the importance of accurate and timely diagnosis, as well as upcoming treatment options.

In his signature Maui Derm NP+PA Fall 2024 session, Shapiro discusses the importance of acting quickly when confronted with a patient who has scarring alopecia.

In a session at Maui Derm NP+PA Fall 2024, Julie Harper, MD, ran through 5 key takeaways for providers managing patients with acne, including where the new triple fixed-dose combination treatment falls in the treatment landscape.

This Maui Derm NP+PA Fall session discusses the latest advancements in hidradenitis suppurativa treatment, the evolving therapeutic landscape, and the critical need for timely diagnosis and aggressive care.

At Maui Derm NP+PA Fall 2024, Ted Rosen, MD, and George Hightower, MD, PhD, review the landscape of infectious diseases that can have dermatologic involvement, including viral, bacterial, fungal, and parasitic illnesses.

At Maui Derm NP+PA Fall 2024, Melodie Young, MSN, ANP-c, reviews new treatment options for pediatric patients with psoriasis and details the difference in disease manifestation between adults and children.

George Martin, MD, and Ted Rosen, MD, reprise their popular session on new therapies and products with a fast and furious rundown of the current armamentarium across disease states.

At Maui Derm NP+PA Fall, Sheila Fallon Friedlander, MD, reviews key findings for the pediatric population from recent dermatology literature, covering topics like cutaneous Crohn’s disease, interrupting the atopic march, advancements in gene therapy, and more.

Joshua Zeichner, MD, delivered a boot camp on isotretinoin use at AAD 2023, including an overview of newer formulations of the acne drug that could help counter the common absorption challenges.

“The present and future is narrow-spectrum antibiotics because they enhance antibiotic stewardship, they protect the host microbiome, [and] they reduce antibiotic resistance,” AAD 2023 presenter Christopher Bunick, MD, PhD, said.

This AAD panel will feature a lively discussion on how to handle difficult or complex medical dermatology cases, with illustrative case studies on dermatomyositis, hidradenitis suppurativa, atopic dermatitis, and more.

Experts will gather for an “Acne Boot Camp” at the American Academy of Dermatology 2023 Annual Meeting to discuss best practices for treating patients with acne.

Han and colleagues will explore the most important factors to consider when selecting an appropriate biologic treatment in an upcoming panel at AAD.

From topical antibiotics like clindamycin to biologic injectables like adalimumab to surgical options like deroofing, treatment for HS can come in many forms.

Emmy Graber, MD, MBA, covered it all in her Winter Clinical Miami talk, offering take-home pearls via patient case studies.

With now more than 6 months of real-world use for baricitinib available, what challenges still remain for the alopecia areata treatment and what other agents are on the horizon?

Treatment is not mandatory and, in fact, clinicians are still without an FDA-approved treatment option, but parents often insist on some sort of action.

Topicals, orals, biologics—Armstrong’s Winter Clinical Miami presentation focused on new treatment options for patients with psoriasis with an emphasis on real-world observations.

Alexandra Golant, MD, and Seemal Desai, MD, weigh the pros and cons of each treatment option for atopic dermatitis, considering mechanism of action, efficacy, and safety. Which will emerge victorious?

“So much new in the world of pediatric dermatology—new and novel treatments for atopic dermatitis, hemangiomas, childhood blistering diseases, warts. We are practicing during the Golden Age of dermatology,” Swanson says.

The proportion of patients who achieved a SALT score < 10 jumped from 24.9% at 36 weeks to 28.9% at 52 weeks in the BARI 4-mg arm and 11.8% to 15.3% in the BARI 2-mg arm.

When evaluating treatment options for patients with psoriasis, rosacea, or eczema, clinicians should employ a top-down approach and remember to consider topical therapies.

Five days of treatment with the topical therapy measurably improved symptoms and emotional/functional impact for patients with actinic keratosis at week 8.

“We're going to talk about medical hair loss in terms of diagnosis and treatment and really try to make it very easy,” Leavitt says.

From deucravacitinib to roflumilast to tralokinumab and everything in between, James Del Rosso, DO, previews his upcoming Winter Clinical Miami session on new therapies.

“It's always a fun, vibrant educational session. We learn tips and advice, and it really is for any injector, both novice [and] advanced. You learn a lot of information,” Ablon says.

“A lot of our colleagues are just getting used to the new biologics for atopic dermatitis like tralokinumab and dupilumab, which have really been breakthroughs in the treatment of atopic dermatitis,” Lebwohl, one of the co-founders of the Fall and Winter Clinical meetings, says.

With an emphasis on real-world applicability and actionable pearls, clinicians gather in Miami to kick off the newest addition to the Fall and Winter Clinical meeting lineup.